ATI-1 是一种自噬 (autophagy) 起始抑制剂,可靶向含缬酪肽蛋白 (VCP/p97),通过破坏其与 UFL1 的相互作用、损害 VCP 相关的 UFM 化稳态、促进 Beclin1 的多泛素化与降解,从而阻断早期自噬体的形成;在营养缺乏条件下,ATI-1 可诱导自噬依赖性恶性肿瘤细胞发生协同性死亡,并伴随线粒体膜电位降低、ROS 水平下降以及溶酶体应激,且在胰腺腺癌异种移植小鼠模型中展现出抗肿瘤功效,可用于胰腺腺癌、肺癌的研究。
产品编号: MS-Y27272 CAS No.: 1242983-93-2 分子式: C16H14F2N2O2S3 分子量: 400.49
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

ATI-1 是一种自噬 (autophagy) 起始抑制剂,可靶向含缬酪肽蛋白 (VCP/p97),通过破坏其与 UFL1 的相互作用、损害 VCP 相关的 UFM 化稳态、促进 Beclin1 的多泛素化与降解,从而阻断早期自噬体的形成;在营养缺乏条件下,ATI-1 可诱导自噬依赖性恶性肿瘤细胞发生协同性死亡,并伴随线粒体膜电位降低、ROS 水平下降以及溶酶体应激,且在胰腺腺癌异种移植小鼠模型中展现出抗肿瘤功效,可用于胰腺腺癌、肺癌的研究。

生物实验数据

生物活性 ATI-1 is an autophagy initiation inhibitor that targets valosin-containing protein (VCP/p97), disrupting its interaction with UFL1, impairing VCP-related UFMylation homeostasis, and promoting Beclin1 polyubiquitination and degradation, thereby blocking early autophagosome formation; under nutrient deprivation, ATI-1 induces synergistic death of autophagy-dependent malignant tumor cells accompanied by decreased mitochondrial membrane potential, reduced ROS levels, and lysosomal stress, and exhibits antitumor efficacy in a pancreatic adenocarcinoma xenograft mouse model, making it applicable for research on pancreatic adenocarcinoma and lung cancer.
体外研究
(In Vitro)

ATI-1 (10 μM; 20 h, plus 20 μM Chloroquine (CQ) (MS-D84251) final 4 h) 可强效抑制 HeLa 细胞中自噬体的形成。
ATI-1 (5-20 μM; 24 h, plus 10 μM for 2 h under EBSS starvation) 可通过降低 Beclin1 蛋白水平并抑制自噬体形成,从而抑制 HeLa 细胞中的自噬起始;可呈剂量依赖性降低 LC3II 水平,而在饥饿条件下则会出现反常的 LC3II 积累。
ATI-1 (5-20 μM; 48 h, plus CQ co-treatment) 可通过降低 Beclin1 蛋白水平,强效抑制自噬依赖型 NCI-H1299 和 MIA PaCa-2 细胞的自噬起始;可呈剂量依赖性降低 LC3II 水平;与 CQ 联用时,还可抑制 MIA PaCa-2 细胞的自噬体形成。
ATI-1 (20 μM; 48-72 h) 可选择性抑制自噬依赖型 NCI-H1299 和 MIA PaCa-2 细胞的增殖、克隆形成能力、迁移及侵袭能力,其效力高于对自噬依赖性较弱的 HeLa 细胞的作用。
ATI-1 (30 μM; 24 h) 可破坏 VCP-UFL1 相互作用,降低 VCP 的 UFMylation 修饰,减弱 VCP-Beclin1 相互作用,并在 HeLa 细胞中选择性损伤特定 VCP 辅因子的相互作用 (VCP-ATXN3、VCP-NPLOC4)。
ATI-1 (3.13-50 μM) 以可测量的亲和力直接结合纯化的全长 VCP (Kd = 25.1 μM) 和纯化的 VCP N 端结构域 (Kd = 32.5 μM)。
ATI-1 (20 μM; 48 h) 在自噬依赖型 NCI-H1299 和 MIA PaCa-2 细胞中诱导 G1 期阻滞,但不会引发显著的细胞凋亡。
ATI-1 (5-10 μM; 2-24 h) 会加剧自噬依赖型 NCI-H1299 和 MIA PaCa-2 细胞在 EBSS 诱导的营养剥夺条件下的代谢脆弱性,进而引发非凋亡性细胞死亡、线粒体膜电位降低、ROS 水平下降以及溶酶体应激;当与饥饿处理联用时,5 μM ATI-1 可在 24 h 内使细胞活力降低约 50%-70%。

Cell Autophagy Assay

Cell Line: HeLa cells
Concentration: 10 μM; 20 μM CQ (final 4 h)
Incubation Time: 20 h; 4 h (CQ)
Result: Markedly reduced the number of autophagosomes per cell.

Western Blot Analysis

Cell Line: HeLa cells
Concentration: 10 μM (with 10 μM CQ final 2 h); 5, 10, 20 μM; 20 μM; 10 μM (EBSS starvation)
Incubation Time: 24 h; 24 h; 24 h; 2 h (EBSS starvation)
Result: Prevented LC3II accumulation seen in the CQ-only group at 10 μM for 24 h with 10 μM CQ for the final 2 h.
Induced a dose-dependent reduction in LC3II levels at 5, 10, 20 μM for 24 h.
Reduced Beclin1 protein levels at 20 μM for 24 h.
Caused a paradoxical accumulation of LC3II under EBSS starvation at 10 μM for 2 h, but autophagic flux analysis confirmed reduced LC3 puncta.

Western Blot Analysis

Cell Line: NCI-H1299 cells, MIA PaCa-2 cells
Concentration: 5, 10, 20 μM (NCI-H1299); 10 μM (NCI-H1299, with 10 μM CQ final 2 h); 5, 10, 20 μM (MIA PaCa-2); 10 μM (MIA PaCa-2, with 10 μM CQ final 2 h); 10 μM (MIA PaCa-2, with 20 μM CQ final 6 h); 20 μM (NCI-H1299, MIA PaCa-2)
Incubation Time: 48 h (NCI-H1299); 48 h (NCI-H1299, plus 2 h CQ); 48 h (MIA PaCa-2); 48 h (MIA PaCa-2, plus 2 h CQ); 48 h (MIA PaCa-2, plus 6 h CQ); 48 h (NCI-H1299, MIA PaCa-2)
Result: Induced a dose-dependent reduction in LC3II levels in both NCI-H1299 and MIA PaCa-2 cells over 48 h.
Significantly reduced LC3II levels in MIA PaCa-2 cells at 10 μM for 48 h with 10 μM CQ for the final 2 h, with less pronounced effect in NCI-H1299 cells.
Reduced yellow autophagosome/autolysosome puncta in MIA PaCa-2 cells at 10 μM for 48 h with 20 μM CQ for the final 6 h compared to CQ alone.
Markedly decreased Beclin1 protein levels in both cell lines at 20 μM for 48 h.

Cell Proliferation Assay

Cell Line: NCI-H1299 cells, MIA PaCa-2 cells, HeLa cells
Concentration: 20 μM
Incubation Time: 72 h (CCK-8); 48 h (colony formation, wound healing, Transwell assays)
Result: Showed more pronounced growth-inhibitory effects in NCI-H1299 and MIA PaCa-2 cells than in HeLa cells, with lower IC50 values across time points.
Significantly inhibited proliferation of NCI-H1299 and MIA PaCa-2 cells at 20 μM for 48 h, while HeLa cells remained relatively resistant.
Markedly abrogated long-term clonogenic capacity and significantly impaired migratory and invasive potential of NCI-H1299 and MIA PaCa-2 cells.

Cell Cycle Analysis

Cell Line: NCI-H1299 cells, MIA PaCa-2 cells
Concentration: 20 μM
Incubation Time: 48 h
Result: Led to G1-phase arrest in both cell lines.
Did not induce obvious apoptosis, with no significant increase in apoptotic populations compared to controls.

Western Blot Analysis

Cell Line: NCI-H1299 cells, MIA PaCa-2 cells
Concentration: 20 μM
Incubation Time: 12 h, 24 h, 48 h
Result: Did not increase γH2AX levels at any time point.
Had little effect on ATXN3 abundance, unlike the canonical VCP inhibitor NMS-873 which induced robust γH2AX and reduced ATXN3 levels.

Western Blot Analysis

Cell Line: NCI-H1299 cells, MIA PaCa-2 cells
Concentration: 10 μM (LC3, ROS, lysosomal, mitochondrial assays); 5 μM (cell viability, apoptosis assays)
Incubation Time: 2 h (LC3, ROS, lysosomal, mitochondrial assays); 24 h (cell viability, apoptosis assays)
Result: Enhanced LC3II accumulation compared to EBSS alone when co-treated with ATI-1 and EBSS.
Reduced cell viability by ~50% within 24 h at 5 μM, and up to ~70% in MIA PaCa-2 cells.
No significant increase in apoptotic populations was observed.
Decreased mitochondrial membrane potential, reduced ROS levels, and caused lysosomal stress with impaired membrane integrity and reduced acidic staining when combined with EBSS.
体内研究
(In Vivo)

ATI-1 (50 mg/kg;腹腔注射;每日一次;连续 14 天) 在 MIA PaCa-2 胰腺腺癌异种移植小鼠模型中展现出强效抗肿瘤功效,可显著降低肿瘤生长水平以及瘤内增殖和自噬标志物水平,且全身毒性极低。

Animal Model: Nude mice
Dosage: 50 mg/kg
Administration: i.p.; daily; 14 days
Result: Significantly suppressed tumor growth, resulting in reduced final tumor weights and volumes compared to controls.
Markedly reduced intratumoral LC3 and Ki-67 expression.
Caused no significant body weight loss or pathological abnormalities in major organs (heart, liver, spleen, lungs, kidneys).

化学信息

分子量 400.49
分子式 C16H14F2N2O2S3
CAS No. 1242983-93-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础